Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | VEGFA | P15692 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PDE1A | P54750 | 1/20 | 0.61 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755741 | 0.87 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL16774566 | 0.85 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30930191 | 0.85 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3549032 | 0.85 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL13986131 | 0.84 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3542660 | 0.84 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL13654775 | 0.84 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL5227988 | 0.84 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL3539891 | 0.84 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| SCHEMBL7365947 | 0.83 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3227155-B2 | — | — | 2001-11-12 | — | — | JP | claimed |
| EP-0526535-B1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | ORION YHTYMAE OY (FI) | 1995-09-27 | — | — | EP | claimed |
| US-5356923-A | 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and anti-hypertensive use thereof | ORION-YHTYMA OY (FI) | 1994-10-18 | — | — | US | claimed |
| EP-0526535-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE. | ORION YHTYMAE OY (FI) | 1993-02-10 | — | — | EP | claimed |
| WO-1991016303-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | Orion-Yhtymä Oy (FI) | 1991-10-31 | — | — | WO | claimed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-0675886-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| EP-0526535-B1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | ORION YHTYMAE OY (FI) | 1995-09-27 | — | — | EP | disclosed |
| US-5356923-A | 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and anti-hypertensive use thereof | ORION-YHTYMA OY (FI) | 1994-10-18 | — | — | US | disclosed |
| US-5356923-A | 1-hydroxy-4(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone and anti-hypertensive use thereof | ORION-YHTYMA OY (FI) | 1994-10-18 | — | — | US | disclosed |
| EP-0526535-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE. | ORION YHTYMAE OY (FI) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991016303-A1 | CYCLIC HYDROXAMIC ACIDS AND THEIR USE | Orion-Yhtymä Oy (FI) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | PDE4A 1771/4885PDE4B 2513/4885PDE4C 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.